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Introduction
Glioblastomas are the most common subtypes of rapidly growing primary brain tumors in adults. Being among the most angiogenic human tumors, they are characterized by remarkable proliferative vascular components and are often necrotic and invasive (1) . Their aggressiveness is mainly due to their ability to stimulate the formation of new blood vessels (2) .
Despite active efforts in therapeutics such as surgery, radiotherapy and chemotherapy, gliomas patients still have a poor prognosis and a high recurrence rate. Since 1980, the median survival of patients with glioblastoma has not increased and remains around 11 months after diagnosis (3) . The lack of efficiency in conventional therapeutic approaches is related to drug delivery challenges inherent to chemoresistance. New therapeutic strategies directed against tumor vasculature or preventing angiogenesis have been developed with exciting preliminary results (4, 5) .
Antiangiogenic drugs are likely to play a key role in the treatment of malignant glioma, mostly in association with other molecularly targeted compounds or with cytotoxic molecules (3, 6) .
In the clinic, the current standard for assessing the efficacy of an anti-tumor therapy is the "Response Evaluation Criteria in Solid Tumor" (RECIST) which is mainly based on measuring tumor volume from radiographic images (7) . Given the observed delay between treatment onset and its effect on tumor size (several weeks or months), an early biomarker of response to therapy would allow rapid treatment adaptation or guide treatment combination, on an individual basis. These biomarkers can arise from biochemical assays (e.g. tissular or circulant markers) or from imaging modalities (8, 9) . Among all imaging modalities, magnetic resonance imaging (MRI) appears as a good candidate for monitoring the effect of anti-tumor therapy. MRI is routinely used to estimate tumor volume using anatomical images, but also tumor associated edema and tumor cellularity, using the apparent diffusion coefficient (ADC) of water (10) (11) (12) . Moreover, numerous microvascular parameters that appear well-suited to assess the effect of antiangiogenic drugs can be estimated using MRI, such as blood volume, blood flow, microvessel diameter, or vessel wall permeability (13) (14) (15) . A recent example shows that the extent of vascular normalization measured by MRI would be predictive of the outcome of anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy in glioblastomas (16) .
Several studies have monitored one or two of these parameters to follow the effect of an anti-tumor therapy in addition to RECIST (17) (18) (19) . Very few therapeutic follow-ups have used an MRI protocol combining more than three parameters (20) .
The aim of this study was to analyze various MR parameters into one protocol to assess the impact of 2 different treatments on glioma model and to evaluate whether these parameters are relevant, i.e. sensitive to a given treatment.
To address this issue, we used a combined MRI / histology protocol to monitor the effect of a cytotoxic therapy (Carmustin / BCNU; an alkylating agent) and of an antiangiogenic therapy (Sorafenib; Nexavar ® ; a multikinase inhibitor) a glioma model obtained by orthotopically xenografting a human glioblastoma cell line (U-87 MG) in Nude rats. BCNU has been chosen because it is one of the standards of care for gliomas. Sorafenib is considered as an antiangiogenic molecule and has been found efficient for several solid tumors (21) . Regarding brain tumors, it was shown that Sorafenib induces growth arrest on a medulloblastoma (22) and a human glioblatoma (23) xenografted grafted in mice. Vascular effects were detected in the last case (23) . Before and three time points after treatment onset, the following MRI parameters were estimated: tumor volume, water ADC, blood volume fraction (BVf), vessel diameter (vessel size index, VSI), and vessel wall integrity (contrast enhancement, CE). The effect of treatments on each of these MRI parameters was assessed and compared to cellular and vascular characteristics described by immunohistochemistry.
Material and methods

Glioma cell line and anti-tumor drugs
The U-87 MG human glioblastoma cell line was purchased from the American 
In vivo intracerebral U-87 MG glioma model and treatments
This study was approved by the local committee for animal care and use (approval 081). Experiments were performed under permits n° A380521, A3851610004 and B3851610003 from the French Ministry of Agriculture.
Experimental design of this study is presented in figure 1a .
Male RH-rnu/rnu Nude rats (n=60, weight: 180-220g, Harlan Sprague Dawley, Indianapolis, USA) were prepared for xenograft by whole body irradiation with a 60 Co !-source (7 Gy), 24-48 h prior to human tumor cell inoculation. Animals were anesthetized with an intraperitoneal injection of Ketamine (75 mg/kg, Ketamine500 ® , Centravet, France) and Xylazine (5 mg/kg, Rompun ® , Centravet, France) in 0.9% NaCl solution and immobilized in a stereotactic frame (David Kopf Instrument, Germany). Five !l of U-87 MG cell suspension in serum-free RPMI1640 medium containing 10 5 tumor cells were inoculated in the right caudate nucleus of the rat brain by stereotactic injection through a 1-mm burr hole at 2.5 mm lateral to the bregma and at a depth of 4.5 mm from the dura. The injection was performed slowly over 15 minutes, and the needle was withdrawn over another 5 minutes. The burr hole was filled with bone wax to prevent extracranial extension of the tumor.
Eleven days after tumor implantation (D11), anatomical imaging (T2-weighted anatomical images) was performed to evaluate the volume of each tumor. Rats were then randomized and stratified in 3 groups (n=20 per group) with the similar average tumor volume per group (mean tumor volume across all rats at D11, 3.8 ± 2.2 mm 3 ).
Treatment began 14 days after tumor implantation ( Fig. 1a ; D14 (T0) ):
-BCNU group received two intravenous injections of BCNU (10 mg.kg -1 ) on the day of treatment onset and 13 days after (D14 (T0) and D27 (T13) ).
-SORA group received daily oral administration of Sorafenib (100 mg.kg -1 ) between treatment onset and the 14 th day after treatment start (D14 (T0) to D28 (T14) ).
-Untreated group received no treatment.
In vivo MRI experiments for tumor follow-up
Experiments were performed on a horizontal 2.35 Tesla (40 cm diameter) magnet equipped with actively shielded gradient coils (Magnex Scientific Ltd., Oxford, UK) and interfaced to a SMIS console (SMIS Ltd, Guildford, UK). MR acquisitions were performed under anesthesia: 5% isoflurane for induction and 2%
for maintenance in 70% air / 30% oxygen. Rectal temperature was maintained at 37.0 ± 0.5°C throughout the experiments. After anesthesia, a catheter was inserted into the tail vein allowing injection of contrast agent without removing the rat from the magnet.
Tumor volume, ADC, BVf, VSI and CE were mapped in the tumor and contralateral hemisphere one day before and 1, 4 and 14 days after treatment onset 
Ex vivo experiments
At the end of the MRI experiment, the animals were humanely sacrified ( Fig. 1a ). The brain was quickly removed, frozen in -40°C isopentane and stored at -80°C until processing. Brains were sliced at -20°C with a cryostat (10 µm thick sections). 
Survival Study
The effects of both treatments on the mean survival of Nude rats bearing a human glioblastoma xenografts were assessed on 6 additional rats per group (untreated, BCNU, and SORA groups) implanted and treated as described above.
Animals were sacrificed at the onset of neurological signs (according to Redgate et al. (25) ). Increased lifespan (ILS) was estimated for each treated group compared (in percent). ILS was calculated using the mean survival time (MST) of each group as following: ILS (%) = (MST untreated -MST treated )/ MST untreated
Control MRI experiment: evaluation of USPIO extravasation
The MR method used to estimate BVf and VSI uses as a starting hypothesis that the contrast agent remains intravascular (26) . 
Data analysis
Determination of tumor volume ( Fig. 1b CE: Vessel integrity was assessed using the T 1w images acquired before (T 1w(before) ) and 3 min after (T 1w(after) ) injection of P846 as describe by equation 1. The mean and standard deviation were computed for each group using the same ROI described above. Since we neglected the plasmatic clearance of USPIO in our analysis, we overestimated the T 1 effects and thus obtained an upper limit of the extravascular iron concentration.
Quantitative histology: Sections corresponding to MRI images (up to three microscopic fields per ROI and animal) were digitized using a CCD camera (Olympus, Rungis, France). Collagen IV images were thresholded and vascular parameters (mean vessel density, fractional vascular surface area, mean vessel radius) were obtained using ImageJ software (Rasband,W.S., ImageJ) as described by Valable et al. (26) . The number of vessels stained by Collagen IV and RecA has been account manually onto the immunohistologies images and then the percentage of vessels doubly stained was calculated. We also realized a manual quantification of the cell density from the HE sections (cells/mm 2 ).
Statistical analysis
Paired t tests were used for comparing tumor versus contralateral striatum inside the same group. Comparisons between each group were subjected to factorial analysis of variance with a Protected Least Significant Difference (PLSD) Fisher's test as post hoc test (intergroup analysis). p<0.05: *; p<0.01: ** and p<0.001: ***.
Survival was visualized using Kaplan-Meier curves and differences between groups assessed with a log-rank test. All statistics were performed with SPSS (SPSS Inc, Chicago, Ill, USA). Results are presented as mean ± standard deviation and are given by group, by time point and by region of interest.
Results
Accuracy of the BVf and VSI measurements
Using our model, accurate BVf and VSI measurements require that the iron- 
Longitudinal MRI follow-up
In a longitudinal study, repeated anesthesia and contrast agent injections might affect the physiological status of the animal, the rate of tumor growth and the accuracy of the MRI measurements. To check this, we compared for each group the "single-time" and the "longitudinal" subgroups at each time point and we observed no difference in body weight, tumor size, ADC, BVf, VSI and in CE between. In this experiment, a longitudinal study (repetition of MRI protocol) has no effect on the assessed parameters. Consequently, for the 3 groups, values from the "single-time"
and "longitudinal" subgroups were pooled at each time-point.
In vivo anti-tumor activity of BCNU and Sorafenib treatments
MRI data in contralateral rat brain hemisphere
No significant difference over time and across the 3 groups in ADC, BVf and VSI was detected contralaterally (720±85 !m$.s -1 , 3.3±0.5% and 5.6±1.1!m for ADC, BVf and VSI mean across time points and groups respectively). Consequently, the mean contralateral value across groups is represented at each time point, for the sake of clarity ( Fig. 3; dotted line) . However, intragroup comparisons between tumor and contralateral tissues were performed using the contralateral values of each group.
U-87 MG tumor development (untreated group)
Median survival time of untreated U-87 MG glioblastoma cells bearing Nude rats was 31 days (Fig. 2a ). The volume of the untreated U-87 MG tumors increased rapidly between D13 (T-1) and D28 (T14) (4.5 ±1.4 to 117.1 ± 22.9 mm 3 respectively; Fig.   2b ). ADC, BVf and VSI in U-87 MG tumors were significantly higher than in the Fig. 3d ).
Effect of BCNU on U-87 MG glioma (BCNU group)
BCNU treatment slightly increased (but not significantly) the median survival of U-87 MG glioma bearing rats (+16%; Fig. 2a ). BCNU treatment strongly inhibited tumor growth compared to untreated group (5.7 ± 4.9 vs. 117.1 ± 22.9 mm 3 , for the BCNU and untreated groups respectively, at D28 (T14) , p<0.001; Fig. 2b ). Intratumoral ADC was comparable between the BCNU and untreated groups at all time points except at D28 (T14) when ADC in the BCNU group became significantly larger than in the untreated group (1048 ± 10 vs. 794 ± 49 !m$.s -1 , p<0.001; Fig. 3a ). VSI, BVf and CE in the BCNU group did not differ from those measured in the untreated group ( Figs. 3b-d ).
Effect of Sorafenib on U-87 MG glioma (SORA group)
Sorafenib treatment induced a small increase (but not significantly) of the median survival time of the U87-MG glioma bearing rats as compared to the untreated group (+23%; Fig. 2a ). Sorafenib treatment significantly inhibited tumor growth as compared to untreated group (28.7 ± 11.1 vs. 117.1 ± 22.9 mm 3 , respectively, at D28 (T14) , p<0.001; Fig. 2b ). We also observe, at D28 (T14) , that the tumoral volume into the SORA group were statistically greater than that of the BCNU group (28.7 ± 11.1 vs. 5.7 ± 4.9 mm 3 , respectively, at D28 (T14) , p<0.001; Fig. 2b ). At D28 (T14) , ADC in the SORA group was larger than in the untreated group (976 ± 37 and 794 ± 49 !m$.s -1 , respectively, p<0.01; Fig. 3a ).
All vascular parameters assessed in this study (VSI, BVf and CE) were 5.5 ± 0.8 %; Fig. 3c ). In contrast to what happens in untreated and BCNU group, in the SORA group the extravasation of P846 was significantly reduced as early as 1 day after Sorafenib treatment start (CE: 116 ± 65% vs 184 ± 42% for the SORA and untreated groups respectively at D15 (T1) ) and was not detectable at D28 (T14) (Fig. 3d ).
HE staining
From D13 (T-1) to D18 (T4) , U-87 MG tumors in the untreated, BCNU and SORA groups presented very similar anatomical histological structures on HE stained sections. Cell density was higher in the tumor core with some tumor cells aligned along vessels, forming thin bundles. Tumors were surrounded by a ring of highly edematous tissue. Neither necrosis nor pseudo-cyst was observed (Fig. 4a) . At D28 (T14) , in the SORA and BCNU groups tumor cell density was reduced compared to previous time points and edematous areas appeared inside the tumor tissue ( Fig. 4a ).
Vascular staining
To assess variation in vasculature properties, collagen IV and RecA labelings were performed (Fig. 4) . For all groups and all time points, vessels in contralateral striatum exhibited similar diameter, density and vascular surface area (4.4 ± 0.2 !m, 337 ± 37 vessels per mm 2 and 3.76 ± 0.34 % vascular surface area; mean across all groups and all time points; Fig. 4b-d ). All vessels were also stained by Collagen IV and RecA (Fig. 4a ). Before treatments, in all groups, tumor vessel diameters were larger than in the contralateral striatum (5.2 ± 0.6; 5.4 ± 0.6 and 6 ± 0.3 !m versus 4.2 ± 0.2 !m for untreated, BCNU and SORA groups versus mean of contralateral striatum across all group, respectively; p<0.05; Fig. 4b ) and vascular surface area was higher than in contralateral striatum (9.1 ± 1.4; 6.2 ± 1.3 and 7.7 ± 0.3 % versus 3.7 ± 0.5 % for untreated, BCNU and SORA groups versus mean of contralateral striatum across all group, respectively; p<0.05; Fig. 4c ). Vascular parameters were stable with time in the untreated and BCNU groups (Fig. 4b-d ).
At D28 (T14) , in the SORA group, tumor vessel density was lower compared to untreated group (141 ± 21 versus 301 ± 60 vessels per mm$ respectively; p<0.01) and vascular area was similar to that in contralateral striatum (3.7 ± 1.4 versus 3.7 ± 0.3 %, respectively; p = 0.45; Fig. 4c ), but vessel diameter was higher than in contralateral striatum (5.8 ± 0.7 versus 4.2 ± 0.1 vessels per mm$, respectively; p<0.05; Fig. 4b ). Finally, only a fraction (63 %; Fig. 4a ) of the tumor vessels stained by Collagen IV antibody was also stained by RecA antibody in SORA group as compared to untreated and BCNU groups (100 %; Fig. 4a ).
Discussion
The effect of two different treatments (BCNU, an alkylating agent and Sorafenib, a multikinase inhibitor) on an orthotopic human glioblastoma xenografted in Nude rats (U-87 MG cell line) was investigated by MRI and by immunohistology.
MRI highlighted an important inhibition of tumor growth induced by both Sorafenib and BCNU treatments. As previously demonstrated, ADC, BVf and VSI values were higher in the tumor tissue than in the contralateral striatum. Sorafenib treatment induced significant differences first on tumor contrast enhancement (D13 (T-1) ), then on BVf and VSI (D18 (T4) ), and finally on ADC and tumor size (D28 (T14) ) compared to control animals. In the BCNU group, only tumor size and ADC were modified 14 days after treatment onset.
As a first prerequisite of this study, we determined whether our extensive MR protocol could be repeated to monitor therapy response on brain tumor. First, we compared for each group the "single-time" and the "longitudinal" subgroups. In each by the occurrence of vasogenic edema. HE staining showed that cell density was smaller in the tumors of treated groups than in the untreated group 14 days after treatment onset. HE staining also showed intratumoral edema in treated groups.
Even if the mechanisms involved in ADC changes are complex, these histological findings could explain the increase in intratumoral ADC in BCNU and SORA groups observed 14 days after treatment onset.
Tumor microvasculature properties assessed by both MRI and histology were not changed by the BCNU treatment. Conversely, Sorafenib induced significant modifications in tumor microvasculature. Four days after antiangiogenic treatment onset, the mean intratumoral BVf was markedly reduced compared to the untreated group and was close to its normal value. This result suggests a tendency towards normalization of tumor vasculature: under antiangiogenic treatment, the tumor vasculature becomes more similar to healthy tissue. However, at the same time point (D18 (T4) ), tumoral VSI was increased by Sorafenib, with values higher than that observed in animals of untreated group. The quantitative immunohistochemistry of tumor vessels confirmed these observations on vessel diameters and also indicated that the vessel density had decreased, as found by Siegelin et al. (23) . The decrease in vessel density observed in immunohistochemistry images is consistent with the decrease in BVf and the concomitant increase in vessel diameter observed by MRI.
In addition to these morphological changes, 1 day after the start of Sorafenib treatment (D15 (T1) ), immunohistochemistry showed some collagen IV-positive vessels without RecA labeling. These observations indicate that some tumor vessels were formed only with basal lamina. This discrepancy between both labelings was even more pronounced after 4 and 14 days of treatment. This has been previously reported in several studies (28, 29) weeks of Sorafenib treatment in patients bearing a renal cell carcinoma (17) .
In our study, BVf and CE parameters indicated a normalization of tumoral vessels under antiangiogenic treatment, which has already been described in several studies (20, 31) . In addition to these two MR parameters, estimates of VSI indicate that tumor vessels had abnormal size compared to vessels in healthy tissue. A normalization of vascular permeability/perfusion associated to an increase in vessel diameters under antiangiogenic treatment has already been described (32 (16) .
Glioblastomas are tumors that are highly resistant to many types of treatment.
Monotherapies with antiangiogenic or cytotoxic drugs, like Sorafenib or BCNU respectively, demonstrated moderate efficacy in the U-87 MG glioblatoma. However, despite their low effectiveness on the overall survival of animals, MRI biomarkers reveal that drugs effectively reach their target and eventually induce both morphological and physiological changes for which drugs were designed. This could be helpful for pharmacological treatment optimization or combination.
The multiparametric MRI approach described in this study allowed the measurement of various characteristics of cellular and vascular remodeling that occurs due to therapy. To further complete this characterization, additional MRI developments can be foreseen or refined analysis could be evaluated. In our study we use a CE-MRI method to evaluate vessel wall integrity. However, this parameter depends on blood flow, vessel wall permeability and diffusion of contrast agent into the extravascular compartment. An appropriate data model (33, 34) could be used to quantify the change in vascular permeability and in blood flow. This requires a protocol optimization to allow measurements of VSI, BVf (using USPIO) and permeability/perfusion (using Gd-based contrast agent) in the same MRI session (35) . Blood flow could also be obtained using Dynamic Susceptibility Contrast MRI or Arterial Spin Labeling (36) . Using a quantitative analysis of T 2 * decay (37) , one could estimate the oxygen extraction fraction in the tumor, a possible marker of tumor hypoxia.
In conclusion, this study indicates that numerous changes occur in the tumor microvasculature and cellularity after antiangiogenic or cytotoxic therapy. This study also indicates that the sensitivity of the studied MR parameters varies for a given treatment and is also treatment dependent. Moreover, these changes appear complex and may not be summarized by a single physiological measurement. MRI appears as an imaging modality that can follow, non-invasively, several microvascular and cellular parameters with a strong potential for the evaluation of new drugs on brain tumors. In addition, these parameters could provide methods to better describe and understand the mechanisms of action of antiangiogenic or antivascular therapies, allowing the rational design of optimized combinations with chemotherapy and/or radiotherapy. 
